| GH | 6.70% | 91.20 | 0.00% | 15,718 | |
| NTRA | 6.61% | 205.22 | +3.58% | 7,131 | |
| KRYS | 5.24% | 258.65 | +1.96% | 4,418 | |
| INSM | 3.89% | 143.13 | +2.14% | 5,932 | |
| UTHR | 3.76% | 529.17 | +10.67% | 1,680 | |
| BBIO | 3.73% | 65.64 | +0.43% | 12,192 | |
| LGND | 3.58% | 208.16 | +3.10% | 3,794 | |
| 207940 | 3.40% | 1,595,000 | +1.01% | 652 | |
| ADPT | 3.35% | 14.950 | +0.61% | 48,245 | |
| AZN | 3.26% | 14,442.0 | -0.40% | 3,589 |
Franklin Templeton ETF Trust - Franklin Genomic Advancements ETF is an exchange traded fund launched by Franklin Resources, Inc. The fund is managed by Franklin Advisers, Inc. It invests in public equity markets of global region. The fund invests in stocks of companies operating across extending and enhancing the quality of human and other life by incorporating technological and scientific developments, improvements and advancements in the field of genomics into their business, such as by offering new products or services that rely on genetic engineering, gene therapy, genome analysis, dna sequencing, synthesis or instrumentation sectors. It invests in growth and value stocks of companies across diversified market capitalization. It invests in stocks of companies that are deemed socially conscious in their business dealings and directly promote environmental responsibility. The fund employs fundamental analysis with bottom-up stock picking approach to create its portfolio. It employs internal and external research to create its portfolio. The fund seeks to benchmark the performance of its portfolio against the Russell 3000 Index. Franklin Templeton ETF Trust - Franklin Genomic Advancements ETF was formed on February 25, 2020 and is domiciled in the United States.